Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind Trial to Evaluate Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine When Administered With Trivalent Inactivated Influenza Vaccine in Adults 65 Years of Age or Older, Naive to 23-Valent Pneumococcal Polysaccharide Vaccine

Trial Profile

A Phase 3, Randomized, Double-Blind Trial to Evaluate Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine When Administered With Trivalent Inactivated Influenza Vaccine in Adults 65 Years of Age or Older, Naive to 23-Valent Pneumococcal Polysaccharide Vaccine

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections; Pneumococcal infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Wyeth
  • Most Recent Events

    • 16 Feb 2012 Actual patient number changed from 1160 to 1185 as reported by ClinicalTrials.gov.
    • 24 May 2011 Results published in the Vaccine.
    • 24 May 2011 Primary endpoint 'Immunological-response' has been met.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top